Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the pharmacokinetics of deferiprone and its
3-O-glucuronide metabolite following administration of a single 1500 mg dose of Ferriprox in
patients with sickle cell disease.